Eupraxia Pharmaceuticals (EPRX) vs Galectin Therapeutics (GALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Eupraxia Pharmaceuticals (EPRX) has outperformed Galectin Therapeutics (GALT) over the past year, gaining 20.5% versus a loss of 16.5%. Eupraxia Pharmaceuticals is the larger company by market cap ($492.9 million vs $397.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EPRX | GALT |
|---|---|---|
| Share price | $7.46 | $3.94 |
| Market cap | $492.91M | $397.35M |
| 1-day change | -1.45% | +8.24% |
| YTD return | -1.19% | -5.29% |
| 1-year return | +20.52% | -16.53% |
| 5-year return | — | +16.91% |
| EPS (TTM) | $-1.02 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.32 | $7.13 |
| 52-week low | $5.25 | $2.03 |
| Distance from 52-week high | -19.96% | -44.74% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +119.17% | +179.19% |
| Average volume | 587.71K | 377.40K |
| Shares outstanding | 66.07M | 100.85M |
| Employees | 49 | 9 |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EPRX has outperformed GALT by 37.0 percentage points over the past year.
About Eupraxia Pharmaceuticals
EPRX stock →Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Health Care · Pharmaceuticals and Biotechnology · 49 employees
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
EPRX vs GALT FAQ
Which is bigger, Eupraxia Pharmaceuticals or Galectin Therapeutics?
Eupraxia Pharmaceuticals (EPRX) is larger, with a market capitalization of $492.91M compared with $397.35M for Galectin Therapeutics (GALT).
Which stock has performed better over the past year, EPRX or GALT?
EPRX returned +20.52% over the past 12 months, compared with -16.53% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are Eupraxia Pharmaceuticals and Galectin Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Pharmaceuticals and Biotechnology for Eupraxia Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Galectin Therapeutics.